Verapamil

Verapamil is a calcium channel blocker. The US label read is for verapamil hydrochloride tablets and lists three groups of uses: angina (angina at rest, including vasospastic and unstable angina, and chronic stable angina); arrhythmias (control of ventricular rate in chronic atrial flutter or atrial fibrillation, in association with digitalis, and prophylaxis of repetitive paroxysmal supraventricular tachycardia); and hypertension, to lower blood pressure. No brand-name tablet label for the immediate-release product was found in openFDA, so this page rests on a generic manufacturer's label. Extended-release products and the injection have their own labels, which were not read.

Also called Verapamil hydrochloride

  • Drug
  • In this atlas

Overview

Technical summary

RxNorm ingredient 11170; UNII V3888OEY5R. The label names the substance as verapamil hydrochloride, so UNII V3888OEY5R is the UNII of the salt form and is a broad match. MeSH descriptor D014700 is Verapamil. Class: Calcium Channel Blocker (FDA established pharmacologic class, RxClass). The label read is the verapamil hydrochloride tablets, Actavis Pharma, Inc. label, effective 2024-01-30 in openFDA (application ANDA070995). Other verapamil labels in openFDA, from other sponsors and repackagers, were not read. This page records label indications and the class only: no trial result and no dose is given.

Trials at a glance

The figures count the 3 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.

Trials
3
Phase 3 or 4
2
Recruiting
1
Regulatory decisions
0
Trials by phase (rows) and registry status (columns)
PhaseRecruitingNot yet recruitingActive, not recruitingAll statuses
Phase 20011
Phase 41102
All phases1113

Conditions these trials study

Sponsors with the most trials

The lead sponsor of each trial, as the registry names it.

About this drug

Level
Substance
Mechanism
Not reported

Classification codes

  • UNII V3888OEY5R

Claims and evidence

Context People for whom the US label of verapamil hydrochloride tablets lists an indication: angina, atrial flutter or fibrillation, supraventricular tachycardia, hypertension

Recipient
Recipient not specified
Population
Patients described in the indications section of the label. The label does not state an age range in the passages read.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
Not stated in the label passages read
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (label statement)
Eligibility: 5 inclusion criteria; exclusion criteria not stated
Included
  • Patients with angina at rest, including vasospastic and unstable angina
  • Patients with chronic stable angina
  • Patients with chronic atrial flutter or atrial fibrillation needing ventricular rate control, in association with digitalis
  • Patients needing prophylaxis of repetitive paroxysmal supraventricular tachycardia
  • Patients with essential hypertension
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The US label of verapamil hydrochloride tablets, in the Actavis Pharma, Inc. version dated 2024-01-30 in openFDA, lists the medicine for angina (angina at rest, including vasospastic and unstable angina, and chronic stable angina); for arrhythmias (control of ventricular rate at rest and during stress, in association with digitalis, in patients with chronic atrial flutter or atrial fibrillation, and prophylaxis of repetitive paroxysmal supraventricular tachycardia); and for the treatment of hypertension, to lower blood pressure.

    Applies to Recipient not specified People for whom the US label of verapamil hydrochloride tablets lists an indication: angina, atrial flutter or fibrillation, supraventricular tachycardia, hypertension

    Certainty method
    Not assessed
    Limitations
    This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-09
    Next evidence check due
    Not scheduled
    Sources and citations (2)
    1. Supports openFDA drug label record for verapamil hydrochloride tablets, Actavis Pharma, Inc. label: indications and substance identifiers

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id a0343397-897b-46d6-943f-a87e07e1de10 (manufacturer Actavis Pharma, Inc., application ANDA070995), returned on 2026-11-09. The label text is dated 2024-01-30 (effective_time). Other openFDA records of verapamil labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0]
      How it applies
      The label sentences that give the indications named in the statement, each quoted in the research quote table.
      Retrieved
      Source effective date
      2024-01-30
      Source state
      Current
      Version fingerprint
      c29bed22ccec22e108dfe8ae23e8b2c021c7d8c27c14deb0f1c2bf7da2406a35
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Background openFDA drug label record for verapamil hydrochloride tablets, Actavis Pharma, Inc. label: indications and substance identifiers

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id a0343397-897b-46d6-943f-a87e07e1de10 (manufacturer Actavis Pharma, Inc., application ANDA070995), returned on 2026-11-09. The label text is dated 2024-01-30 (effective_time). Other openFDA records of verapamil labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20240130.
      Retrieved
      Source effective date
      2024-01-30
      Source state
      Current
      Version fingerprint
      c29bed22ccec22e108dfe8ae23e8b2c021c7d8c27c14deb0f1c2bf7da2406a35
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

FDA label

The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.

CALAN

No label from the application holder was found in the openFDA label dataset for application NDA018817. This page does not show another labeler's label in its place.

CALAN

No label from the application holder was found in the openFDA label dataset for application NDA019038. This page does not show another labeler's label in its place.

CALAN SR

No label from the application holder was found in the openFDA label dataset for application NDA019152. This page does not show another labeler's label in its place.

COVERA-HS

No label from the application holder was found in the openFDA label dataset for application NDA020552. This page does not show another labeler's label in its place.

ISOPTIN

No label from the application holder was found in the openFDA label dataset for application NDA018485. This page does not show another labeler's label in its place.

ISOPTIN

No label from the application holder was found in the openFDA label dataset for application NDA018593. This page does not show another labeler's label in its place.

TARKA

No label from the application holder was found in the openFDA label dataset for application NDA020591. This page does not show another labeler's label in its place.

VERAPAMIL HYDROCHLORIDE

No label from the application holder was found in the openFDA label dataset for application NDA018925. This page does not show another labeler's label in its place.

VERELAN

No label from the application holder was found in the openFDA label dataset for application NDA019614. This page does not show another labeler's label in its place.

VERELAN PM

No label from the application holder was found in the openFDA label dataset for application NDA020943. This page does not show another labeler's label in its place.

FDA decisions timeline

The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.

  1. Approval NDA018485 ISOPTIN
  2. Approval NDA018593 ISOPTIN
  3. Approval NDA018925 VERAPAMIL HYDROCHLORIDE
  4. Approval NDA019038 CALAN
  5. Approval NDA018817 CALAN
  6. Supplemental approval NDA018593 ISOPTIN
  7. Supplemental approval NDA018593 ISOPTIN
  8. Supplemental approval NDA018817 CALAN
  9. Approval NDA019152 CALAN SR
  10. Supplemental approval NDA018817 CALAN
  11. Supplemental approval NDA019152 CALAN SR
  12. Approval NDA019614 VERELAN
  13. Approval NDA020552 COVERA-HS
  14. Approval NDA020591 TARKA
  15. Approval NDA020943 VERELAN PM

Clinical links

Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.

Registry records

Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.

Registry products 10

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA018485

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 2 efficacy supplement approvals on record.

    ProductNDA018593

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 2 efficacy supplement approvals on record.

    ProductNDA018817

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA018925

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA019038

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 1 efficacy supplement approval on record.

    ProductNDA019152

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA019614

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA020552

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA020591

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA020943

Registry trials 3

Record details

Record id
cardio:verapamil
Content hash
eabbf4dbac6a8c1ccf83fe9587ddc65a286941674d18cc961ef475e783500fe7